Ifosfamide in testicular cancer

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Ifosfamide has demonstrated significant activity as salvage therapy in patients with testicular tumors refractory to cisplatin-containing induction chemotherapy regimens. Used as a single agent, ifosfamide produces objective responses in approximately 1 of 5 heavily pretreated patients failing to respond to any other agents. When ifosfamide is administered in combination with cisplatin and other agents, approximately 40% to 50% of pretreated patients with recurrent germ cell tumors achieve a complete remission. Studies currently under way should determine the optimal use of ifosfamide against testicular neoplasms, including its possible role as part of initial induction therapy.

Original languageEnglish
Pages (from-to)2-5
Number of pages4
JournalSeminars in Oncology
Volume17
Issue number2 SUPPL. 4
StatePublished - 1990

Fingerprint

Ifosfamide
Testicular Neoplasms
Cisplatin
Salvage Therapy
Induction Chemotherapy
Germ Cell and Embryonal Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Ifosfamide in testicular cancer. / Loehrer, Patrick.

In: Seminars in Oncology, Vol. 17, No. 2 SUPPL. 4, 1990, p. 2-5.

Research output: Contribution to journalArticle

Loehrer, P 1990, 'Ifosfamide in testicular cancer', Seminars in Oncology, vol. 17, no. 2 SUPPL. 4, pp. 2-5.
Loehrer, Patrick. / Ifosfamide in testicular cancer. In: Seminars in Oncology. 1990 ; Vol. 17, No. 2 SUPPL. 4. pp. 2-5.
@article{3b6360c260474c56bfd0976c1c257151,
title = "Ifosfamide in testicular cancer",
abstract = "Ifosfamide has demonstrated significant activity as salvage therapy in patients with testicular tumors refractory to cisplatin-containing induction chemotherapy regimens. Used as a single agent, ifosfamide produces objective responses in approximately 1 of 5 heavily pretreated patients failing to respond to any other agents. When ifosfamide is administered in combination with cisplatin and other agents, approximately 40{\%} to 50{\%} of pretreated patients with recurrent germ cell tumors achieve a complete remission. Studies currently under way should determine the optimal use of ifosfamide against testicular neoplasms, including its possible role as part of initial induction therapy.",
author = "Patrick Loehrer",
year = "1990",
language = "English",
volume = "17",
pages = "2--5",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "2 SUPPL. 4",

}

TY - JOUR

T1 - Ifosfamide in testicular cancer

AU - Loehrer, Patrick

PY - 1990

Y1 - 1990

N2 - Ifosfamide has demonstrated significant activity as salvage therapy in patients with testicular tumors refractory to cisplatin-containing induction chemotherapy regimens. Used as a single agent, ifosfamide produces objective responses in approximately 1 of 5 heavily pretreated patients failing to respond to any other agents. When ifosfamide is administered in combination with cisplatin and other agents, approximately 40% to 50% of pretreated patients with recurrent germ cell tumors achieve a complete remission. Studies currently under way should determine the optimal use of ifosfamide against testicular neoplasms, including its possible role as part of initial induction therapy.

AB - Ifosfamide has demonstrated significant activity as salvage therapy in patients with testicular tumors refractory to cisplatin-containing induction chemotherapy regimens. Used as a single agent, ifosfamide produces objective responses in approximately 1 of 5 heavily pretreated patients failing to respond to any other agents. When ifosfamide is administered in combination with cisplatin and other agents, approximately 40% to 50% of pretreated patients with recurrent germ cell tumors achieve a complete remission. Studies currently under way should determine the optimal use of ifosfamide against testicular neoplasms, including its possible role as part of initial induction therapy.

UR - http://www.scopus.com/inward/record.url?scp=0025338788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025338788&partnerID=8YFLogxK

M3 - Article

C2 - 2159186

AN - SCOPUS:0025338788

VL - 17

SP - 2

EP - 5

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 2 SUPPL. 4

ER -